Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

(177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.

Name: Kaimen Rigor review — (177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.
Item: (177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.
Rating: 100
Author: Alpha1

Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, Crosby M, Piulats JM, Fléchon A, Wei XX, Mahammedi H, Roubaud G, Študentová H, Nagarajah J, Mellado B, Montesa-Pino Á, Kpamegan E, Ghebremariam S, Kreisl TN, Wilke C, Lehnhoff K, Sartor O, Fizazi K, PSMAfore Investigators

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 3★ (Adequate), 0 critical, 2 high issues for “(177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Read alongside

(177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.

Read full text (PMC)

DOI

10.1016/S0140-6736(24)01653-2

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/e8617547-d674-4e9f-a2cc-0b290de2ba8e" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/e8617547-d674-4e9f-a2cc-0b290de2ba8e/badge" alt="Kaimen Rigor review — 3★ (Adequate), 0 critical, 2 high issues for “(177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

c67c6f09af70324b57ac734b729cc7df50bd0ff2b253b67b557c9480f90c1a77

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

(177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.

Paper source

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint is radiographic progression-free survival (rPFS), a surrogate for clinical benefit. The paper does not demonstrate target engagement at the tested dose (no PK/PD or dose-exposure data) and does not cite validated evidence linking rPFS to overall survival or other hard clinical outcomes in this setting. Overall survival, a hard endpoint, showed no difference (HR 0.98, 95% CI 0.75-1.28).
“The primary endpoint was rPFS, defined as time from randomisation to radiographic disease progression (by BICR as per PCWG3-modified RECIST v1·1), or death.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary effect is a prolongation of rPFS (median 11.60 vs 5.59 months, HR 0.49). However, rPFS is a surrogate, and the magnitude is not anchored to a minimal clinically important difference or to a hard clinical outcome. Overall survival showed no benefit (HR 0.98). Thus, the clinical meaningfulness of the rPFS effect is not established.
“the hazard ratio for radiographic progression or death with 177 Lu-PSMA-617 vs ARPI change was 0·41 (95% CI, 0·29–0·56; two-sided p<0·0001); the median rPFS was 9·30 months (95% CI, 6·77–not estimable [NE]) vs 5·55 months (4·04–5·95)”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 05AvailabilityNone found 06Copyedit6 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted phase 3 randomized controlled trial with rigorous design, clear reporting of ethics, demographics, and statistical methods. The main weaknesses are minor reporting gaps: statistical software not named, CONSORT guideline not explicitly mentioned, and a few copyedit issues including inconsistent p-value formatting and an internal contradiction in the number of randomized patients.

Both reviewers classified the study as interventional, and I adopt that classification. The evaluation covered the full text, with verification components checking citations, statistics, reproducibility, preregistration, and integrity. Bench-related criteria (cell lines, antibodies, etc.) were not applicable for this drug trial.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Overstated conclusions

2 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

6 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

None found

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Checked — nothing surfaced.

Eight Dimensions8 pass

The introduction cites VISION and TheraP trials, acknowledges their limitations (post-taxane setting), and provides a logical rationale for testing 177Lu-PSMA-617 in taxane-naive patients. The limitations of prior work are addressed by designing a trial in a different patient population.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior trials (VISION, TheraP) and explaining the unmet need in taxane-naive mCRPC patients.

Evidence

“The VISION trial demonstrated the efficacy of 177 Lu-PSMA-617 in this post-taxane mCRPC setting, with significant prolongation of radiographic progression-free survival (rPFS) and overall survival following addition of 177 Lu-PSMA-617 to standard of care vs standard of care alone.”

Introduction ¶3Find in source

“Therefore, there remains an unmet need for therapy options among patients who wish to defer taxane-based chemotherapy.”

Introduction ¶1Find in source

paraphrase[Introduction, paragraph 3]

“Paraphrase: The authors note that VISION and TheraP were in post-taxane settings, and PSMAfore addresses the taxane-naive population.”

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with prior work cited and a logical rationale for the trial.

Evidence

Introduction ¶3Find in source

“PSMAfore is a phase 3 trial that was designed to compare 177 Lu-PSMA-617 with a change of ARPI in taxane-naive patients with mCRPC who had progressed once on ARPI as last therapy, and were considered candidates for ARPI change.”

Introduction ¶4Find in source

paraphrase[Introduction, paragraph 3]

“Paraphrase: The paper notes that prior evidence was in post-taxane patients, and PSMAfore addresses the taxane-naive setting.”

Randomization used interactive response technology with stratification factors. The trial is open-label with a stated rationale (different administration routes and radiation regulations). Power analysis is provided for the primary endpoint. Inclusion/exclusion criteria are detailed. The analysis population (ITT for efficacy, safety population for safety) is defined.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous: randomized, stratified, with prespecified endpoints, power analysis, and clear inclusion/exclusion criteria.

Evidence

“Randomisation was performed using interactive response technology and was stratified according to previous ARPI use (castration-resistant vs hormone-sensitive prostate cancer), and by pain symptoms (asymptomatic or mildly symptomatic vs symptomatic; score of 0–3 vs >3 on item 3 of the screening Brief Pain Inventory - Short Form [BPI-SF]).”

MethodsFind in source

“The primary analysis of rPFS was prespecified to occur after approximately 156 events in 450 patients, providing 95% power to detect a hazard ratio (HR) of 0·56 at an overall one-sided α of 0·025.”

Statistical analysisFind in source

“Finally, double-blinding was not possible in this trial because of the different administration routes of the trial interventions and because of radiation protection regulations and ethical considerations.”

Discussion ¶6Find in source

PASSReviewer 2· 95% conf

The trial design is rigorous with adequate randomization, blinding of central reviewers, power analysis, and pre-specified endpoints.

Evidence

MethodsFind in source

“Independent central reviewers were blinded to randomised treatment assignment.”

MethodsFind in source

Statistical analysisFind in source

The study is in prostate cancer, so all participants are male; sex is reported implicitly. Age, race, ECOG status, disease sites, and laboratory values are reported in Table 1. Since both sexes are not applicable (prostate cancer), sex_justified is not applicable. Demographics are adequate.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Patient demographics and baseline characteristics are well reported, including age, sex (all male), race, and disease-related variables.

Evidence

“Age Median (IQR) – years | 71·0 (12·0) | 72·0 (10·0)”

Table 1Find in source

“ECOG performance status – no. (%) 0 | 146 (62) | 116 (50)”

Table 1Find in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including age, sex, race, and disease status.

Evidence

“Age Median (IQR) – years | 71·0 (12·0) | 72·0 (10·0)”

Table 1Find in source

“OMB category – no. (%) White | 212 (91) | 214 (91)”

Table 1Find in source

“ECOG performance status – no. (%) 0 | 146 (62) | 116 (50)”

Table 1Find in source

The paper states that independent ethical review boards at all sites approved the protocol and all patients provided written informed consent. It also states compliance with Declaration of Helsinki and Good Clinical Practice. This satisfies all applicable criteria.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals and consent are adequately reported: named ethics boards approved, written informed consent obtained, and compliance with Helsinki and GCP stated.

Evidence

paraphrase[Methods, Trial oversight]

“Independent ethical review boards at all sites approved the protocol (available at thelancet.com). All patients provided written informed consent.”

paraphrase[Methods, Trial oversight]

“PSMAfore (ClinicalTrials.gov number, NCT04689828) was conducted in accordance with the Declaration of Helsinki principles and Good Clinical Practice guidelines.”

PASSReviewer 2· 95% conf

Ethical approvals and informed consent are clearly documented.

Evidence

paraphrase[Methods, Trial oversight]

“Independent ethical review boards at all sites approved the protocol (available at thelancet.com).”

“All patients provided written informed consent.”

MethodsFind in source

paraphrase[Methods, Trial oversight]

“PSMAfore (ClinicalTrials.gov number, NCT04689828) was conducted in accordance with the Declaration of Helsinki principles and Good Clinical Practice guidelines.”

The trial uses a drug (177Lu-PSMA-617) and comparators (abiraterone, enzalutamide). The paper names the drugs, doses, and regimens. Since this is a drug trial, bench criteria are not applicable. Software tools are not described in detail, but the statistical software is not specified; however, this is not a key resource for a clinical trial.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedNOT REPORTED

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (177Lu-PSMA-617) and comparator ARPIs are identified with dose and regimen; no other key biological resources are used.

Evidence

paraphrase[Methods, Design and interventions]

“Patients were randomised 1:1 to receive either 177 Lu-PSMA-617 7·4 GBq (200 mCi) ± 10% once every 6 weeks for six cycles, or a change of ARPI to abiraterone or enzalutamide as per treating investigator selection.”

“In the ARPI change group, the median duration of exposure was 6·52 months (IQR, 7·77); 100 patients received abiraterone and 132 patients received enzalutamide.”

ResultsFind in source

PASSReviewer 2· 85% conf

The investigational product and key software are identified adequately.

Evidence

“177 Lu-PSMA-617 7·4 GBq (200 mCi) ± 10% once every 6 weeks for six cycles”

MethodsFind in source

“a change of ARPI to abiraterone or enzalutamide as per treating investigator selection”

MethodsFind in source

absence[Methods, Statistical analyses]

Statistical software is not explicitly named.

The paper names the tests (log-rank, Cox proportional hazards, Kaplan-Meier) and provides exact p-values (e.g., p<0.0001) and confidence intervals. Effect sizes are reported as hazard ratios with CIs. Data presentation includes Kaplan-Meier curves and forest plots. Mathematical plausibility is not applicable for large-N continuous outcomes. Software is not explicitly identified, but this is a minor omission.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedNOT REPORTED

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described: log-rank test, Cox model, Kaplan-Meier, with exact p-values and confidence intervals.

Evidence

“Time-to-event endpoints were assessed using the log-rank test stratified by the randomisation factors. Hazard ratios and confidence intervals (CIs) were estimated using the stratified Cox proportional-hazards model.”

Statistical analysisFind in source

“the hazard ratio for radiographic progression or death with 177 Lu-PSMA-617 vs ARPI change was 0·41 (95% CI, 0·29–0·56; two-sided p<0·0001)”

ResultsFind in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with CIs.

Evidence

Statistical analysisFind in source

“the hazard ratio for radiographic progression or death with 177 Lu-PSMA-617 vs ARPI change was 0·41 (95% CI, 0·29–0·56; two-sided p<0·0001)”

ResultsFind in source

“the hazard ratio for radiographic progression or death with 177 Lu-PSMA-617 vs ARPI change was 0·41 (95% CI, 0·29–0·56; two-sided p<0·0001)”

ResultsFind in source

The data availability statement names a specific platform (clinicalstudydatarequest.com) and describes the review process. This is a managed-access route, which is adequate for individual patient data. Repository deposit and accession numbers are not applicable for patient-level data. Code sharing is not applicable as no bespoke code is mentioned.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data sharing is described with a concrete mechanism (clinicalstudydatarequest.com) and conditions, which is adequate for patient-level data.

Evidence

paraphrase[Data sharing section]

“Data availability for this trial is according to the criteria and process described on www.clinicalstudydatarequest.com.”

PASSReviewer 2· 90% conf

Data sharing is described with a concrete mechanism (clinicalstudydatarequest.com).

Evidence

paraphrase[Data sharing section]

“Data availability for this trial is according to the criteria and process described on www.clinicalstudydatarequest.com.”

The trial is registered (NCT04689828). Methods are comprehensive. Limitations are explicitly discussed (open-label, crossover, generalizability). Conclusions are proportional to the evidence. Funding and conflicts of interest are disclosed. Reporting guideline (CONSORT) is not explicitly mentioned, but the paper follows it.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial is registered, methods are detailed, limitations are discussed, and funding/COI are disclosed.

Evidence

paraphrase[Abstract, Funding]

“ClinicalTrials.gov (http://clinicaltrials.gov), NCT04689828”

“This study has several limitations. Firstly, it did not examine a higher risk population for whom taxane-based chemotherapy was the most appropriate next therapy after progression on an ARPI, therefore, the results cannot be generalised to this population.”

Discussion ¶6Find in source

“This trial was funded by Novartis.”

FundingFind in source

PASSReviewer 2· 95% conf

The trial is registered, methods are complete, limitations are discussed, and funding/COI are disclosed.

Evidence

paraphrase[Summary, Funding]

“ClinicalTrials.gov (http://clinicaltrials.gov), NCT04689828”

Discussion ¶5Find in source

“This trial was funded by Novartis.”

FundingFind in source

Registered (7 IDs: ClinicalTrials.gov, Clinical Trials Registry – India). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 55 references by DOI: 47 verified — 8 no DOI (shown, not verified).

7 of 8 data/code links checked; 7 live; 1 not probed.

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly typo, consistency, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and well-reported. An informed reader should weigh the minor reporting gaps (software not named, CONSORT not mentioned) and the internal contradiction in the number of randomized patients (468 vs 470) as low-severity issues that do not undermine the main conclusions. No erratum is warranted for these minor issues, but the authors may consider clarifying the randomization count and p-value formatting in a correction.

1.
HIGHreporting
Clarify the total number of randomized patients: the abstract reports 468, but the CONSORT diagram mentions additional patients randomized but excluded. Specify the exact number randomized and the reasons for exclusion in the CONSORT flow.
The internal contradiction between 468 and 470 randomized patients could confuse readers and reviewers; a clear CONSORT flow resolves this.
2.
HIGHcopyedit
Correct the p-value formatting for the non-significant overall survival result: change 'p<0.44' to 'p=0.44' in the Abstract and Results.
Using '<' for a non-significant p-value is inconsistent and could be misread as a threshold; standard reporting uses '=' for exact p-values.
3.
MEDIUMreporting
Explicitly name the statistical software (e.g., SAS version) used for analyses in the Methods, Statistical analyses section.
Both reviewers flagged the absence of software identification as a minor reporting gap; naming the software improves reproducibility.
4.
MEDIUMreporting
Mention adherence to CONSORT reporting guidelines in the Methods or a separate section.
Explicitly stating CONSORT adherence strengthens reporting transparency and is expected for a randomized trial.
5.
MEDIUMdata code
Provide a link to the full protocol and statistical analysis plan in the Data Sharing statement.
Both reviewers suggested this to enhance transparency and allow readers to verify prespecified analyses.
6.
MEDIUMstatistics
Clarify how p-values were converted to two-sided for the primary endpoint in the Methods, Statistical analyses section.
The copyedit flagged this as unclear; specifying the conversion method (e.g., multiply by 2) improves methodological clarity.
7.
MEDIUMreporting
Define the abbreviation 'OMB' (Office of Management and Budget) in the Table 1 footnote.
The copyedit noted the abbreviation is not defined; defining it improves readability.
8.
LOWcopyedit
Add a note to Table 1 that some percentages are based on non-missing data, as suggested in the copyedit.
Clarifying the denominator for percentages improves transparency of baseline characteristics.
9.
LOWreporting
Consider reporting the number of patients with HRR mutations if available, to address the limitation regarding generalizability.
Reviewer 2 suggested this to strengthen the discussion of generalizability.
10.
LOWstatistics
Clarify the handling of missing data for patient-reported outcomes in the statistical methods.
Reviewer 2 raised this as a potential gap; specifying the imputation or analysis method improves reproducibility.

Full text (52,334 chars)Analyzed: Aug 16, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

(177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.

Read full text (PMC)

DOI

10.1016/S0140-6736(24)01653-2

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/e8617547-d674-4e9f-a2cc-0b290de2ba8e" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/e8617547-d674-4e9f-a2cc-0b290de2ba8e/badge" alt="Kaimen Rigor review — 3★ (Adequate), 0 critical, 2 high issues for “(177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

c67c6f09af70324b57ac734b729cc7df50bd0ff2b253b67b557c9480f90c1a77

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint is radiographic progression-free survival (rPFS), a surrogate for clinical benefit. The paper does not demonstrate target engagement at the tested dose (no PK/PD or dose-exposure data) and does not cite validated evidence linking rPFS to overall survival or other hard clinical outcomes in this setting. Overall survival, a hard endpoint, showed no difference (HR 0.98, 95% CI 0.75-1.28).
“The primary endpoint was rPFS, defined as time from randomisation to radiographic disease progression (by BICR as per PCWG3-modified RECIST v1·1), or death.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary effect is a prolongation of rPFS (median 11.60 vs 5.59 months, HR 0.49). However, rPFS is a surrogate, and the magnitude is not anchored to a minimal clinically important difference or to a hard clinical outcome. Overall survival showed no benefit (HR 0.98). Thus, the clinical meaningfulness of the rPFS effect is not established.
“the hazard ratio for radiographic progression or death with 177 Lu-PSMA-617 vs ARPI change was 0·41 (95% CI, 0·29–0·56; two-sided p<0·0001); the median rPFS was 9·30 months (95% CI, 6·77–not estimable [NE]) vs 5·55 months (4·04–5·95)”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 05AvailabilityNone found 06Copyedit6 minor suggestions

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Overstated conclusions

2 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

6 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

None found

Checked — nothing surfaced.

Eight Dimensions8 pass

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior trials (VISION, TheraP) and explaining the unmet need in taxane-naive mCRPC patients.

Evidence

Introduction ¶3Find in source

“Therefore, there remains an unmet need for therapy options among patients who wish to defer taxane-based chemotherapy.”

Introduction ¶1Find in source

paraphrase[Introduction, paragraph 3]

“Paraphrase: The authors note that VISION and TheraP were in post-taxane settings, and PSMAfore addresses the taxane-naive population.”

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with prior work cited and a logical rationale for the trial.

Evidence

Introduction ¶3Find in source

Introduction ¶4Find in source

paraphrase[Introduction, paragraph 3]

“Paraphrase: The paper notes that prior evidence was in post-taxane patients, and PSMAfore addresses the taxane-naive setting.”

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous: randomized, stratified, with prespecified endpoints, power analysis, and clear inclusion/exclusion criteria.

Evidence

MethodsFind in source

Statistical analysisFind in source

Discussion ¶6Find in source

PASSReviewer 2· 95% conf

The trial design is rigorous with adequate randomization, blinding of central reviewers, power analysis, and pre-specified endpoints.

Evidence

MethodsFind in source

“Independent central reviewers were blinded to randomised treatment assignment.”

MethodsFind in source

Statistical analysisFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Patient demographics and baseline characteristics are well reported, including age, sex (all male), race, and disease-related variables.

Evidence

“Age Median (IQR) – years | 71·0 (12·0) | 72·0 (10·0)”

Table 1Find in source

“ECOG performance status – no. (%) 0 | 146 (62) | 116 (50)”

Table 1Find in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including age, sex, race, and disease status.

Evidence

“Age Median (IQR) – years | 71·0 (12·0) | 72·0 (10·0)”

Table 1Find in source

“OMB category – no. (%) White | 212 (91) | 214 (91)”

Table 1Find in source

“ECOG performance status – no. (%) 0 | 146 (62) | 116 (50)”

Table 1Find in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals and consent are adequately reported: named ethics boards approved, written informed consent obtained, and compliance with Helsinki and GCP stated.

Evidence

paraphrase[Methods, Trial oversight]

“Independent ethical review boards at all sites approved the protocol (available at thelancet.com). All patients provided written informed consent.”

paraphrase[Methods, Trial oversight]

“PSMAfore (ClinicalTrials.gov number, NCT04689828) was conducted in accordance with the Declaration of Helsinki principles and Good Clinical Practice guidelines.”

PASSReviewer 2· 95% conf

Ethical approvals and informed consent are clearly documented.

Evidence

paraphrase[Methods, Trial oversight]

“Independent ethical review boards at all sites approved the protocol (available at thelancet.com).”

“All patients provided written informed consent.”

MethodsFind in source

paraphrase[Methods, Trial oversight]

“PSMAfore (ClinicalTrials.gov number, NCT04689828) was conducted in accordance with the Declaration of Helsinki principles and Good Clinical Practice guidelines.”

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedNOT REPORTED

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (177Lu-PSMA-617) and comparator ARPIs are identified with dose and regimen; no other key biological resources are used.

Evidence

paraphrase[Methods, Design and interventions]

“In the ARPI change group, the median duration of exposure was 6·52 months (IQR, 7·77); 100 patients received abiraterone and 132 patients received enzalutamide.”

ResultsFind in source

PASSReviewer 2· 85% conf

The investigational product and key software are identified adequately.

Evidence

“177 Lu-PSMA-617 7·4 GBq (200 mCi) ± 10% once every 6 weeks for six cycles”

MethodsFind in source

“a change of ARPI to abiraterone or enzalutamide as per treating investigator selection”

MethodsFind in source

absence[Methods, Statistical analyses]

Statistical software is not explicitly named.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedNOT REPORTED

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described: log-rank test, Cox model, Kaplan-Meier, with exact p-values and confidence intervals.

Evidence

Statistical analysisFind in source

“the hazard ratio for radiographic progression or death with 177 Lu-PSMA-617 vs ARPI change was 0·41 (95% CI, 0·29–0·56; two-sided p<0·0001)”

ResultsFind in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with CIs.

Evidence

Statistical analysisFind in source

“the hazard ratio for radiographic progression or death with 177 Lu-PSMA-617 vs ARPI change was 0·41 (95% CI, 0·29–0·56; two-sided p<0·0001)”

ResultsFind in source

“the hazard ratio for radiographic progression or death with 177 Lu-PSMA-617 vs ARPI change was 0·41 (95% CI, 0·29–0·56; two-sided p<0·0001)”

ResultsFind in source

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data sharing is described with a concrete mechanism (clinicalstudydatarequest.com) and conditions, which is adequate for patient-level data.

Evidence

paraphrase[Data sharing section]

“Data availability for this trial is according to the criteria and process described on www.clinicalstudydatarequest.com.”

PASSReviewer 2· 90% conf

Data sharing is described with a concrete mechanism (clinicalstudydatarequest.com).

Evidence

paraphrase[Data sharing section]

“Data availability for this trial is according to the criteria and process described on www.clinicalstudydatarequest.com.”

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial is registered, methods are detailed, limitations are discussed, and funding/COI are disclosed.

Evidence

paraphrase[Abstract, Funding]

“ClinicalTrials.gov (http://clinicaltrials.gov), NCT04689828”

Discussion ¶6Find in source

“This trial was funded by Novartis.”

FundingFind in source

PASSReviewer 2· 95% conf

The trial is registered, methods are complete, limitations are discussed, and funding/COI are disclosed.

Evidence

paraphrase[Summary, Funding]

“ClinicalTrials.gov (http://clinicaltrials.gov), NCT04689828”

Discussion ¶5Find in source

“This trial was funded by Novartis.”

FundingFind in source

Registered (7 IDs: ClinicalTrials.gov, Clinical Trials Registry – India). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 55 references by DOI: 47 verified — 8 no DOI (shown, not verified).

7 of 8 data/code links checked; 7 live; 1 not probed.

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly typo, consistency, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHreporting
Clarify the total number of randomized patients: the abstract reports 468, but the CONSORT diagram mentions additional patients randomized but excluded. Specify the exact number randomized and the reasons for exclusion in the CONSORT flow.
The internal contradiction between 468 and 470 randomized patients could confuse readers and reviewers; a clear CONSORT flow resolves this.
2.
HIGHcopyedit
Correct the p-value formatting for the non-significant overall survival result: change 'p<0.44' to 'p=0.44' in the Abstract and Results.
Using '<' for a non-significant p-value is inconsistent and could be misread as a threshold; standard reporting uses '=' for exact p-values.
3.
MEDIUMreporting
Explicitly name the statistical software (e.g., SAS version) used for analyses in the Methods, Statistical analyses section.
Both reviewers flagged the absence of software identification as a minor reporting gap; naming the software improves reproducibility.
4.
MEDIUMreporting
Mention adherence to CONSORT reporting guidelines in the Methods or a separate section.
Explicitly stating CONSORT adherence strengthens reporting transparency and is expected for a randomized trial.
5.
MEDIUMdata code
Provide a link to the full protocol and statistical analysis plan in the Data Sharing statement.
Both reviewers suggested this to enhance transparency and allow readers to verify prespecified analyses.
6.
MEDIUMstatistics
Clarify how p-values were converted to two-sided for the primary endpoint in the Methods, Statistical analyses section.
The copyedit flagged this as unclear; specifying the conversion method (e.g., multiply by 2) improves methodological clarity.
7.
MEDIUMreporting
Define the abbreviation 'OMB' (Office of Management and Budget) in the Table 1 footnote.
The copyedit noted the abbreviation is not defined; defining it improves readability.
8.
LOWcopyedit
Add a note to Table 1 that some percentages are based on non-missing data, as suggested in the copyedit.
Clarifying the denominator for percentages improves transparency of baseline characteristics.
9.
LOWreporting
Consider reporting the number of patients with HRR mutations if available, to address the limitation regarding generalizability.
Reviewer 2 suggested this to strengthen the discussion of generalizability.
10.
LOWstatistics
Clarify the handling of missing data for patient-reported outcomes in the statistical methods.
Reviewer 2 raised this as a potential gap; specifying the imputation or analysis method improves reproducibility.

Full text (52,334 chars)Analyzed: Aug 16, 2026